Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR)
NCT ID: NCT03807492
Last Updated: 2025-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
241 participants
OBSERVATIONAL
2019-01-16
2024-02-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
NCT05627219
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
NCT04447703
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
NCT03934606
Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting
NCT03912883
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
NCT04266431
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EMPOWeR Study
This is a cohort study, with initial patient assessments and longitudinal follow-up. Participation of subjects will be indefinite, which will be discussed in the informed consent.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Unaffected males who are at higher risk for prostate cancer (family history of prostate cancer or African American males)
* Men who previously tested positive for a mutation may be eligible for Specific Aims 2-7
* Men with a known familial mutation
* Men who previously participated in the Genetic Evaluation of Men (GEM) study (IRB#14S.546) will be offered participation in EMPOWeR -
Exclusion Criteria
* Mental or cognitive impairment that interferes with ability to provide informed consent
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sidney Kimmel Cancer Center at Thomas Jefferson University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Thomas Jefferson University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JT 13180
Identifier Type: OTHER
Identifier Source: secondary_id
18D.644
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.